TPIV 200

Drug Profile

TPIV 200

Alternative Names: Folate receptor alpha vaccine; Folate receptor alpha-loaded dendritic cell vaccine; FR alpha peptide vaccine; FRa peptide vaccine; FRalphaDC; HuFR-1; Multi-epitope folate receptor alpha peptide vaccine; TPIV200

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; TapImmune
  • Class Cancer vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Ovarian cancer
  • Phase I Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 30 Dec 2016 Phase-II clinical trials in Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA (Intradermal)
  • 11 Aug 2016 TapImmune initiates enrolment in the third phase II trial in Solid tumours before August 2016
  • 01 May 2016 Phase-II clinical trials in Ovarian cancer (Combination therapy, Second line therapy or greater) in USA (Intradermal) (NCT02764333)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top